Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 3/20 | 0.32 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20121971 | 0.86 | MITF (0.32) | MITF | |
| SCHEMBL19558652 | 0.82 | MITF (0.33) | MITF | |
| SCHEMBL14769651 | 0.80 | AR (0.33) | MITF | |
| SCHEMBL22480890 | 0.80 | MITF (0.32) | MITF | |
| SCHEMBL799935 | 0.80 | MEN1 (0.32) | MITFMEN1KMT2ALMNA | |
| SCHEMBL9769187 | 0.80 | MITF (0.32) | MITF | |
| SCHEMBL11977475 | 0.80 | L3MBTL1 (0.32) | MITFL3MBTL1 | |
| SCHEMBL21720376 | 0.80 | MITF (0.32) | MITF | |
| SCHEMBL21720511 | 0.80 | MITF (0.32) | MITF | |
| SCHEMBL19011087 | 0.78 | MITF (0.32) | MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709719-A1 | 5-CYANO-1H-IMIDAZOLE-2-CARBOXAMIDE COMPOUNDS AS CSF1R INHIBITORS | Modulo Bio, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024254440-A1 | 5-CYANO-1H-IMIDAZOLE-2-CARBOXAMIDE COMPOUNDS AS CSF1R INHIBITORS | MODULO BIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240018279-A1 | Cyclic Containing Polymer Compositions Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018279-A1 | Cyclic Containing Polymer Compositions Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11807635-B2 | Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-11-07 | — | — | US | disclosed |
| US-20230348642-A1 | Ethylene-Alpha-Olefin-Diene Monomer Copolymers Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Homogeneous Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-11-02 | — | — | US | disclosed |
| EP-0771822-A1 | Catalytic system for the (co)polymerization of alpha-olefins | ENICHEM S.p.A. (IT) | 1997-05-07 | — | — | EP | disclosed |
| EP-0121838-B1 | PROCESS FOR THE PREPARATION OF 1,4-SUBSTITUTED 2-BUTENE-1,4-DIONES | BASF Aktiengesellschaft (DE) | 1986-02-26 | — | — | EP | disclosed |
| US-4513150-A | Preparation of but-2-ene-1,4-diones substituted in the 1,4-positions | BASF AKTIENGESELLSCHAFT (DE) | 1985-04-23 | — | — | US | disclosed |
| EP-0121838-A1 | Process for the preparation of 1,4-substituted 2-butene-1,4-diones | BASF Aktiengesellschaft (DE) | 1984-10-17 | — | — | EP | disclosed |
| EP-0041775-B1 | PROCESS FOR THE PREPARATION OF ALKYL FURANS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-07-18 | — | — | EP | disclosed |
| EP-0032290-B1 | PROCESS FOR THE PREPARATION OF 1,4-DIALKYLBUT-2-ENE-1,4-DIONES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-03-14 | — | — | EP | disclosed |
| US-4340764-A | OXIDIZING 2,5-DIALKYLFURAN | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-07-20 | — | — | US | disclosed |
| US-4323509-A | Process for the preparation of alkyl furans | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-04-06 | — | — | US | disclosed |
| EP-0041775-A1 | Process for the preparation of alkyl furans | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-12-16 | — | — | EP | disclosed |
| EP-0032290-A2 | Process for the preparation of 1,4-dialkylbut-2-ene-1,4-diones | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807635-B2 | Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof | DPP4, DPP3, DPP9 | MITF 4202/4885MEN1 3665/4885KMT2A 4601/4885 |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | MITF 1405/4885MEN1 524/4885KMT2A 4004/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | MITF 3085/4885MEN1 3254/4885KMT2A 1342/4885 |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | MITF 2909/4885MEN1 4705/4885KMT2A 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.